Cargando…

Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present phase I–II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity of the docetaxel–ifosfamide combination in this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, C, Tsavaris, N, Malamos, N, Stavroyianni, N, Gregoriou, A, Rokana, S, Polyzos, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747562/ https://www.ncbi.nlm.nih.gov/pubmed/12698179 http://dx.doi.org/10.1038/sj.bjc.6600887

Ejemplares similares

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
por: Kosmas, C, et al.
Publicado: (2009)

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998)

Phase I study of docetaxel plus ifosfamide in patients with advanced cancer
por: Marx, G, et al.
Publicado: (2002)

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
por: Lortholary, A, et al.
Publicado: (2003)

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
por: Awada, A, et al.
Publicado: (2008)

Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours
por: Kosmas, C, et al.
Publicado: (2011)

Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours
Publicado: (1998)

Possible metabolic interaction between docetaxel and ifosfamide
por: Ando, Y
Publicado: (2000)

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
por: Batista, N, et al.
Publicado: (2004)

Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
por: Miller, Devon, et al.
Publicado: (2022)

Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
por: Colia, Vittoria, et al.
Publicado: (2017)

Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
por: Kang, Heeseok, et al.
Publicado: (2009)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
por: Georgoulias, V, et al.
Publicado: (2004)

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
por: Talbot, D C, et al.
Publicado: (2002)

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
por: Lordick, F, et al.
Publicado: (2003)

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study
por: John, Matthias, et al.
Publicado: (2012)

Ifosfamide ±VP16 in Childhood' Malignancy: A Phase II (toxicity) Study
por: Pizer, B., et al.
Publicado: (1988)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
por: Yamaguchi, K, et al.
Publicado: (2006)

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
por: Park, Se Hoon, et al.
Publicado: (2005)

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study
por: Scinto, A F, et al.
Publicado: (1999)

Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
por: Tsavaris, N, et al.
Publicado: (2002)

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
por: González-Manzano, R., et al.
Publicado: (1995)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Partial Fanconi Syndrome Induced by Ifosfamide
por: Das, Sulagna, et al.
Publicado: (2019)

High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.
por: Gomm, S. A., et al.
Publicado: (1991)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer
por: Kiura, K, et al.
Publicado: (2003)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy
por: Luan, Xiao-Dong, et al.
Publicado: (2017)

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
por: Fruscio, R, et al.
Publicado: (2008)

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
por: Katsumata, N, et al.
Publicado: (2005)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tco4731u9rt8rqvtpbk7fdqdtg